Praxis precision medicines highlights 2025 corporate strategy and business priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028

PRAX Ratings Summary

PRAX Quant Ranking